Auteur T. WINHUSEN

  Tris disponibles Ajouter le résultat à votre sélection

  Affiner la recherche

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience

L. AMASS ; W. LING ; T. E. FREESE ; C. REIBER ; J. J. ANNON ; A. J. COHEN ; D. McCARTY ; M. S. REID ; L. S. Jr BROWN ; C. CLARK ; ZIEDONIS D. M. ; J. KREJCI ; STINE S. ; T. WINHUSEN ; G. BRIGHAM ; D. BABCOCK ; MUIR J. A. ; B. J. BUCHAN ; T. HORTON | 2004
Dans American Journal on Addictions (Vol.13, Suppl.1, May-June 2004) Article : Périodique

In October 2002, the US Food and Drug Administration approved buprenorphine-naloxone (Suboxone) sublingual tablets as an opioid dependence treatment available for use outside traditionally licensed opioid treatment programs. The NIDA Center for [...]

Plus d'info

Ajouter à la sélection

Lien externe

The HPA axis in cocaine use: implications for pharmacotherapy

T. WINHUSEN ; SOMOZA E. | 2001
Périodique

ENGLISH : The role of the hypothalamic-pituitary-adrenal (HPA) axis in cocaine use is reviewed within the context of two approaches to developing pharmacological treatments in humans: (1) reducing the reinforcing effects of cocaine and (2) red[...]

Plus d'info

Ajouter à la sélection

Using buprenorphine short-term taper to facilitate early treatment engagement

G. S. BRIGHAM ; L. AMASS ; T. WINHUSEN ; J. M. HARRER ; A. PELT | 2007
Dans Journal of Substance Abuse Treatment (Vol.32, n°4, June 2007) Article : Périodique

The U.S. Federal Food and Drug Administration approved buprenorphine for drug abuse treatment in 2002, and it became available for clinical use in early 2003. Maryhaven, a community treatment program, participated in a National Institute on Drug[...]

Plus d'info

Ajouter à la sélection